Cefovecin

Overview

Cefovecin (Convenia®) is a long-acting, third-generation cephalosporin antibiotic administered by subcutaneous injection in dogs and cats. It is FDA-approved in the United States for the treatment of specific skin infections in both species.

A key advantage of cefovecin is its prolonged duration of action following a single injection, due to extensive plasma protein binding and a long elimination half-life. This makes it particularly useful in patients where oral antibiotic administration is difficult, poorly tolerated, or unlikely to be completed reliably by the owner.

Mechanism of Action (MOA): Cefovecin is a bactericidal beta-lactam antibiotic that binds to bacterial penicillin-binding proteins (PBPs), disrupting cell wall synthesis and leading to bacterial cell death. Although classified as a third-generation cephalosporin, its activity against gram-negative organisms is more limited compared to other drugs in this class, and it is not effective against Pseudomonas spp., methicillin-resistant staphylococci, or enterococci.

Because third-generation cephalosporins are considered critically important in human medicine, cefovecin use in dogs and cats should be based on appropriate case selection and, whenever possible, culture and susceptibility results.

Indications

Cefovecin is indicated in dogs and cats for the treatment of specific susceptible bacterial infections, primarily involving the skin and soft tissues. Because of its long duration of action, it is most appropriate in patients where oral antimicrobial therapy is not feasible or adherence is a concern.

• Canine skin infections (label use – FDA-approved): Treatment of secondary superficial pyoderma, abscesses, and wounds caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (group G).
• Feline skin infections (label use – FDA-approved): Treatment of wounds and abscesses caused by susceptible strains of Pasteurella multocida.
• Skin and soft tissue infections (extra-label): May be used for other susceptible organisms in dogs and cats based on culture and susceptibility testing.
• Urinary tract infections (extra-label): May be considered for UTIs caused by susceptible organisms (e.g., Escherichia coli) when oral treatment is problematic. Use should be guided by culture results and clinical judgment.
• Adjunctive therapy for periodontal disease (extra-label): Used in combination with appropriate dental procedures for severe infections of the gingival and periodontal tissues caused by susceptible organisms.
• Lyme disease (extra-label, dogs): Two doses given 14 days apart have been shown to be effective in eliminating spirochetes and reducing antibody levels in experimentally induced canine Lyme borreliosis.
• Outpatient management of canine parvoviral enteritis (selected cases): May be considered as part of a supportive outpatient protocol when hospitalization is not possible, in combination with intensive supportive care.

Cefovecin should not be routinely extrapolated to systemic gram-negative infections outside of UTIs, as its high protein binding may limit effective free drug concentrations in some infections.

Dosage (Reference)

Dog

Cefovecin is administered as a single subcutaneous (SC) injection at a labeled dose of 8 mg/kg.
Because of its prolonged half-life, therapeutic concentrations are maintained for an extended period after one injection.

Cat

In cats, cefovecin is administered as a single subcutaneous injection at 8 mg/kg.
Therapeutic concentrations are maintained for approximately 7 days for labeled Pasteurella multocida infections.

Warnings & Precautions

Cefovecin is a long-acting third-generation cephalosporin. Because of its prolonged persistence in the body and its importance in human medicine, careful patient selection and antimicrobial stewardship are essential.

• Hypersensitivity reactions: Contraindicated in patients with a known hypersensitivity to cephalosporins. Use cautiously in animals with a documented allergy to other beta-lactam antibiotics (e.g., penicillins, carbapenems) due to potential cross-reactivity. Anaphylaxis has been reported.
• Age restrictions: Safe use has not been established in dogs or cats younger than 4 months of age. In some countries, use is discouraged in animals younger than 8 weeks.
• Route of administration: Safety has not been established for IV or IM administration. Cefovecin should be administered subcutaneously only.
• Renal impairment: Use cautiously in patients with significant renal dysfunction. Dose adjustment may be necessary in severe renal disease, although specific adjustment guidelines are not established.
• Prolonged persistence: Cefovecin may persist in the body for up to 65 days. If adverse effects occur, they may require prolonged management due to the drug’s extended elimination time.
• Antimicrobial stewardship: Third-generation cephalosporins are classified as critically important antimicrobials. Use should be based on culture and susceptibility whenever possible and reserved for appropriate indications.
• Breeding and lactation: Safe use in breeding, pregnant, or lactating animals has not been established. Use only when benefits outweigh potential risks.
• Human safety: Individuals with known beta-lactam allergies should exercise caution when handling the product.
• Medication errors: Cefovecin may be confused with other cephalosporins. Clear prescribing and labeling practices are recommended to avoid errors.

Drug Interactions

Cefovecin is highly bound to plasma proteins. Theoretically, it may displace other highly protein-bound drugs, causing transient increases in free (active) drug concentrations. Although clinically significant interactions are considered unlikely, monitoring for adverse effects is recommended when cefovecin is used concurrently with the following medications.

• Highly protein-bound drugs: Concurrent use may temporarily increase free drug concentrations of either agent. Monitor patients for unexpected adverse effects.
• Carprofen (NSAID): In vitro studies show increased free carprofen concentrations; however, clinical significance appears minimal based on available data. Monitor for NSAID-related adverse effects.
• Other NSAIDs: Theoretical risk of increased free drug levels due to protein-binding competition. Monitor for gastrointestinal or renal adverse effects.
• Furosemide: Increased free concentrations observed in experimental systems. Monitor hydration status and renal parameters when used together.
• Doxycycline: Increased free drug concentrations reported in vitro. Clinical impact is unclear; monitor as appropriate.
• Ketoconazole: Increased free concentrations demonstrated in vitro. Monitor for potential adverse effects.
• Other highly protein-bound medications: Includes drugs such as maropitant, anticonvulsants, cardiac medications, propofol, and behavioral medications. Although clinical relevance has not been established, observe for altered drug responses.

Because cefovecin has prolonged persistence, any interaction—if clinically significant—may also have a prolonged duration.

Side Effects & Overdose

Side Effects

Cefovecin is generally well tolerated in dogs and cats; however, adverse effects can occur. Because the drug persists in the body for an extended period (up to approximately 65 days), adverse reactions may also be prolonged.

• Gastrointestinal effects: Vomiting, diarrhea, and anorexia have been reported in both dogs and cats.
• Lethargy / depression: Reported in post-marketing surveillance in both species.
• Injection site reactions: Pain, swelling, or local irritation may occur following SC administration.
• Hypersensitivity reactions: Allergic reactions, including anaphylaxis and death, have been reported. Immediate veterinary intervention is required if suspected.
• Hematologic effects: Cephalosporins have been associated with neutropenia, anemia, thrombocytopenia, hypoprothrombinemia, prolonged PT/PTT, platelet dysfunction, and, rarely, toxic neutropenia (especially when combined with NSAIDs).
• Laboratory changes: Mild to moderate increases in liver enzymes (e.g., ALT, GGT) have been observed in dogs. In cats, increases in BUN and creatinine and mild ALT elevations have been reported.
• Antimicrobial resistance: Increased beta-lactam–resistant fecal E. coli has been documented following treatment.

Overdose

Acute overdose of cefovecin is unlikely to result in life-threatening toxicity, but adverse effects may occur at high doses.

• Dogs (up to 180 mg/kg SC, ≈22.5× label dose): Injection site irritation, vocalization, edema, vomiting, and diarrhea were observed. Edema typically resolved within 8–24 hours.
• Cats (up to 180 mg/kg SC, ≈22.5× label dose): Similar gastrointestinal and injection site effects; decreased mean WBC counts were observed 10 days post-treatment, and one cat developed mild bilirubinuria.
• Management: Treatment is supportive and symptomatic. Because of prolonged drug persistence, monitoring may need to continue for an extended period if adverse effects develop.

Key Notes

Practical clinical considerations for the appropriate and responsible use of cefovecin in dogs and cats:

• Long duration after single dose: One injection provides extended antimicrobial coverage, which can improve compliance in patients where oral therapy is unreliable.
• Not a substitute for culture: Whenever possible, perform culture and susceptibility testing before administration, especially in recurrent or deep infections.
• Limited gram-negative reliability: Do not extrapolate susceptibility results from other third-generation cephalosporins to cefovecin.
• Systemic E. coli infections: Not ideal for systemic (non-UTI) Enterobacterales infections due to high protein binding and limited free drug concentrations.
• Resistance selection pressure: Use judiciously to reduce the risk of promoting beta-lactam resistance in commensal bacteria.
• Post-treatment urine culture timing: Because of prolonged excretion, follow-up urine cultures (when indicated) may be reasonably performed about 3 weeks after the last injection.
• Reconstitution: Reconstitute with 10 mL sterile water for injection to yield a concentration of 80 mg/mL. Shake and allow complete dissolution before use.
• Storage after reconstitution: Refrigerate (2–8°C), protect from light, do not freeze, and discard unused product after 56 days.